Pyxis Oncology (NASDAQ: PYXS) is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company generates no product revenue as of FY2025, operating entirely on capital raised through equity issuances, including private placements, an at-the-market program, and pre-funded warrants. Its lead investigational asset is MICVO, an antibody-drug conjugate being evaluated in a Phase 1/2 study (PYX-201-102) in patients with first-line and second-line-plus recurrent or metastatic head and neck squamous cell carcinoma, at dose levels between 3.6 mg/kg and 5.4 mg/kg in combination with pembrolizumab. A second asset, PYX-106, is an investigational Siglec-15-targeting IgG1 antibody with worldwide rights outside Greater China. Both PYX-106 and other preclinical programs are currently paused, with the company seeking partnership or collaboration arrangements for those assets. Thomas Civik serves as Interim Chief Executive Officer as of the 10-K filed March 23, 2026.

Revenue model

No product revenue as of FY2025. The company funds operations through equity capital raises, including private placements, an ATM common stock program, and issuance of pre-funded warrants. Deferred revenues appear on the balance sheet but no material product or royalty revenue is disclosed in the filing excerpts.

Products and services

MICVO: investigational antibody-drug conjugate in clinical development for recurrent or metastatic head and neck squamous cell carcinoma (PYX-201-102 study, doses 3.6 to 5.4 mg/kg IV in combination with pembrolizumab 200 mg IV Q3W). PYX-106: investigational fully human IgG1 Siglec-15-targeting antibody designed to block T-cell suppression; worldwide rights excluding Greater China; program currently paused and available for partnership.

Customers and end markets

No commercial customers as of FY2025. End market is oncology, specifically patients with recurrent or metastatic head and neck squamous cell carcinoma. Future revenue, if any, would depend on third-party payor coverage under Medicare Parts B and D, commercial insurance, and managed care organizations.

Value-chain role

Clinical-stage drug developer. The company designs and develops investigational oncology assets through clinical trials and seeks partnership or out-licensing arrangements for paused programs. No manufacturing or commercialization activities are disclosed in the filing excerpts.

Geographic exposure

Incorporated and headquartered in the United States. PYX-106 license covers worldwide rights excluding Greater China (mainland China, Hong Kong, Macau). No other geographic revenue or operational detail is supported by the filing excerpts.

Source: SEC 10-K, filed 2026-03-23

Industry: Pharmaceutical Preparations Peers: X4 Pharmaceuticals Inc ZEO ScientifiX Inc Bolt Biotherapeutics Inc Curis Inc Senti Biosciences Inc Korro Bio Inc ImmuCell Corp Synlogic Inc SQZ Biotechnologies Co